|
FY2023
12 months to Jan 31, 2023
|
FY2022
12 months to Jan 31, 2022
|
FY2021
12 months to Jan 31, 2021
|
|
|---|---|---|---|
| Cash flows from operating activities | |||
| Net loss | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | |||
| Amortization of deferred sales commissions | |||
| Amortization (accretion) of marketable securities purchased at a premium (discount) | |||
| Stock-based compensation, net of amounts capitalized | |||
| Impairment of capitalized internal-use software | |||
| Non-cash operating lease cost | |||
| Other | |||
| Changes in operating assets and liabilities, net of impact of acquisitions: | |||
| Accounts receivable | |||
| Prepaid expenses | |||
| Other assets | |||
| Deferred sales commissions | |||
| Accounts payable | |||
| Accrued expenses and other current liabilities | |||
| Deferred revenue | |||
| Operating lease liabilities | |||
| Other liabilities | |||
| Net cash used in operating activities | |||
| Cash flows from investing activities | |||
| Purchases of marketable securities | |||
| Maturities of marketable securities | |||
| Sales of marketable securities | |||
| Purchases of property and equipment | |||
| Capitalized internal-use software costs | |||
| Cash paid for acquisitions, net of cash and restricted cash acquired | |||
| Net cash provided by (used in) investing activities | |||
| Cash flows from financing activities | |||
| Proceeds from initial public offering, net of underwriting discounts | |||
| Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs | |||
| Proceeds from borrowings | |||
| Repayment of borrowings | |||
| Payments of deferred offering costs | |||
| Proceeds from employee stock purchase plan | |||
| Proceeds from exercise of common stock options | |||
| Cash paid for holdback consideration in connection with acquisitions | |||
| Net cash provided by financing activities | |||
| Effect of exchange rate changes on cash and cash equivalents | |||
| Change in cash and cash equivalents and restricted cash | |||
| Beginning of period | |||
| End of period | |||
| Supplemental disclosures of cash flow information | |||
| Cash paid for income taxes | |||
| Cash paid for interest | |||
| Supplemental non-cash investing and financing information | |||
| Conversion of redeemable convertible preferred stock to common stock | |||
| Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital | |||
| Vesting of early exercised options | |||
| Common stock and assumed awards issued as consideration for acquisitions | |||
| Unpaid cash consideration for acquisitions | |||
| Stock-based compensation capitalized as internal-use software costs | |||
| Issuance of redeemable convertible preferred stock warrants | |||
| Deferred offering costs accrued but not yet paid | |||
| Property and equipment accrued but not yet paid | |||
| Reconciliation of cash, cash equivalents, and restricted cash to consolidated balance sheets | |||
| Cash and cash equivalents | |||
| Restricted cash included in other current assets |
Loading...